ECSP11010856A - Composición farmacéutica sólida - Google Patents

Composición farmacéutica sólida

Info

Publication number
ECSP11010856A
ECSP11010856A EC2011010856A ECSP11010856A ECSP11010856A EC SP11010856 A ECSP11010856 A EC SP11010856A EC 2011010856 A EC2011010856 A EC 2011010856A EC SP11010856 A ECSP11010856 A EC SP11010856A EC SP11010856 A ECSP11010856 A EC SP11010856A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
solid pharmaceutical
diuretic
formula
compound represented
Prior art date
Application number
EC2011010856A
Other languages
English (en)
Inventor
Junya Nomura
Yutaka Tanoue
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11010856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP11010856A publication Critical patent/ECSP11010856A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una preparación sólida que contiene un compuesto representado por la fórmula (I)donde cada símbolo es como se define en la memoria descriptiva, o una sal del mismo, un agente de control del pH y un diurético, el cual es superior en la propiedad de estabilidad y disolución del compuesto representado por la fórmula (I) y el diurético.
EC2011010856A 2008-07-31 2011-02-28 Composición farmacéutica sólida ECSP11010856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8520108P 2008-07-31 2008-07-31
US8562708P 2008-08-01 2008-08-01

Publications (1)

Publication Number Publication Date
ECSP11010856A true ECSP11010856A (es) 2011-03-31

Family

ID=41610805

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010856A ECSP11010856A (es) 2008-07-31 2011-02-28 Composición farmacéutica sólida

Country Status (26)

Country Link
US (1) US9169238B2 (es)
EP (1) EP2310385B1 (es)
JP (1) JP5635491B2 (es)
KR (1) KR20110038145A (es)
CN (1) CN102164918B (es)
AR (1) AR072883A1 (es)
AU (1) AU2009277455A1 (es)
BR (1) BRPI0916847A2 (es)
CA (1) CA2732018C (es)
CL (1) CL2011000187A1 (es)
CO (1) CO6341633A2 (es)
CR (1) CR20110111A (es)
DO (1) DOP2011000032A (es)
EA (1) EA201170273A1 (es)
EC (1) ECSP11010856A (es)
GE (1) GEP20146062B (es)
IL (1) IL210819A0 (es)
MA (1) MA32553B1 (es)
MX (1) MX2011001150A (es)
NZ (1) NZ590948A (es)
PE (1) PE20110551A1 (es)
PT (1) PT2310385T (es)
TW (1) TW201008915A (es)
UY (1) UY32017A (es)
WO (1) WO2010013835A2 (es)
ZA (1) ZA201100871B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
US20140348915A9 (en) * 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
JP6935301B2 (ja) * 2016-11-18 2021-09-15 花王株式会社 モノハロゲノアミン製造用被覆粒子群
IN202021028444A (es) * 2020-07-03 2022-01-28
CN117503719A (zh) * 2023-12-06 2024-02-06 烟台万润药业有限公司 一种美阿沙坦钾片剂及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) * 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US20030068374A1 (en) * 2000-02-21 2003-04-10 Shigeru Kamei Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
JP2001294524A (ja) 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd アセトアミノフェン配合内服固形製剤
FR2812876B1 (fr) * 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
KR20030097892A (ko) * 2001-05-25 2003-12-31 에스에스 세야쿠 가부시키 가이샤 의약 배합제
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
EP1648515B1 (en) 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7625940B2 (en) * 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
KR20070053239A (ko) 2004-09-06 2007-05-23 코와 가부시키가이샤 사구체 질환 치료제
US20070049636A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
EA200701159A1 (ru) 2004-12-17 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид
NZ562887A (en) * 2005-03-30 2010-10-29 Takeda Pharmaceutical Benzimidazole derivative and use as angiotensin II antagonist
JP2008540573A (ja) 2005-05-13 2008-11-20 マイクロビア インコーポレーテッド ４−ビアリーリル−１−フェニラゼチジン−２−オン類
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
GEP20125420B (en) * 2006-08-10 2012-03-26 Takeda Pharmaceutical Solid pharmaceutical composition comprising benzimidazole compound
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
AR065850A1 (es) 2007-03-28 2009-07-08 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
RU2010104960A (ru) 2007-08-01 2011-09-10 Тева Фармасьютикал Индастриес Лтд. (Il) Фармацевтическая композиция кандесартана
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
PT2310385T (pt) 2017-09-11
JP5635491B2 (ja) 2014-12-03
CR20110111A (es) 2011-04-28
WO2010013835A3 (en) 2010-06-10
CN102164918A (zh) 2011-08-24
US20110123615A1 (en) 2011-05-26
EA201170273A1 (ru) 2011-08-30
MA32553B1 (fr) 2011-08-01
BRPI0916847A2 (pt) 2016-02-10
ZA201100871B (en) 2012-05-30
DOP2011000032A (es) 2011-02-28
UY32017A (es) 2010-02-26
US9169238B2 (en) 2015-10-27
MX2011001150A (es) 2011-03-29
AU2009277455A1 (en) 2010-02-04
CN102164918B (zh) 2014-05-07
TW201008915A (en) 2010-03-01
CL2011000187A1 (es) 2011-06-24
AR072883A1 (es) 2010-09-29
EP2310385A2 (en) 2011-04-20
IL210819A0 (en) 2011-04-28
NZ590948A (en) 2012-06-29
CA2732018A1 (en) 2010-02-04
KR20110038145A (ko) 2011-04-13
JP2011529444A (ja) 2011-12-08
CO6341633A2 (es) 2011-11-21
WO2010013835A2 (en) 2010-02-04
EP2310385B1 (en) 2017-06-07
GEP20146062B (en) 2014-03-25
PE20110551A1 (es) 2011-09-02
CA2732018C (en) 2017-07-04

Similar Documents

Publication Publication Date Title
CR20110209A (es) Composición farmacéutica sólida
CO6341633A2 (es) Composicion farmaceutica solida
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
BR112014017749A8 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
UY32644A (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
CO6351738A2 (es) Compuestos organicos
CR20120448A (es) Compuesto heterocíclico
EA201270216A1 (ru) Фармацевтический состав
SV2011003855A (es) Heteroarilos sustituidos
EA201170772A1 (ru) Органические соединения
BR112012012903A2 (pt) compostos de espiropiperidina
DOP2011000329A (es) Preparacion de solido
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
BR112015029504A2 (pt) inibidores quinase
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112016011778A2 (pt) Pirazol fluorofenila, seus usos, e composição farmacêutica
CY1112501T1 (el) Φαρμακευτικες συνθεσεις περιεχουσες λεφλουνομιδη
BR112012012987A2 (pt) derivados de diona espiroheterocíclica utilizados como pesticidas.
ATE535230T1 (de) Fosphenytoin-zusammensetzung
UA103905C2 (ru) Твердая фармацевтическая композиция
TN2011000045A1 (en) Solid pharmaceutical composition